Products for Research Use Only

Tyk2-IN-22-d3

CAT: 0804-HY-169984SSize: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-169984SSize:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Tyk2-IN-22-d3 (Compound 1) is the deuterated analog of Tyk2-IN-22. Tyk2-IN-22 (Compound A8) is a selective inhibitor for tyrosine kinase 2 (Tyk2), that it inhibits Tyk2, JAK1, and JAK3 with IC50s of 9.7, 148.6, and 883.3 nM, respectively. Tyk2-IN-22 inhibits the downstream STAT5 phosphorylation[1][2].
CAS Number
1771691-32-7
UNSPSC
12352005
Target
Isotope-Labeled Compounds; JAK; STAT
Related Pathways
Epigenetics; JAK/STAT Signaling; Others; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Smiles
COC1=C(C2=NN(C)N=N2)C=CC=C1NC3=CC(NC(C4CC4)=O)=NC=C3C(NC([2H])([2H])[2H])=O
Molecular Formula
C20H19D3N8O3
Molecular Weight
425.46
References & Citations
[1]AM Subbaiah M, et al. Prodrug Strategy to Address Impaired Oral Absorption of a Weakly Basic TYK2 Inhibitor Caused by a Gastric Acid-Reducing Agent[J]. Journal of Medicinal Chemistry, 2024, 67 (22) : 20664-20681.|[2]Istanbullu H, et al. Discovery of selective TYK2 inhibitors: Design, synthesis, in vitro and in silico studies of promising hits with triazolopyrimidinone scaffold[J]. Bioorganic Chemistry, 2024, 148: 107430.|[3]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported
Isoform
STAT5